Abstract:Liver X receptors (LXRs) have been recognized as a promising therapeutic target for atherosclerosis; however, their role in insulin sensitivity is controversial. Adiponectin plays a unique role in maintaining insulin sensitivity. Currently, no systematic experiments elucidating the role of LXR activation in insulin function based on adiponectin signaling have been reported. Here, we investigated the role of LXR activation in insulin resistance based on adiponectin signaling, and possible mechanisms. C57BL/6 mice maintained on a regular chow received the LXR agonist, T0901317 (30 mg/kg.d) for 3 weeks by intraperitoneal injection, and differentiated 3T3-L1 adipocytes were treated with T0901317 or GW3965. T0901317 treatment induced significant insulin resistance in C57BL/6 mice. It decreased adiponectin gene transcription in epididymal fat, as well as serum adiponectin levels. Activity of AMPK, a key mediator of adiponectin signaling, was also decreased, resulting in decreased Glut-4 membrane translocation in epididymal fat. In contrast, adiponectin activity was not changed in the liver of T0901317 treated mice. In vitro, both T0901317 and GW3965 decreased adiponectin expression in adipocytes in a dose-dependent manner, an effect which was diminished by LXR alpha silencing. ChIP-qPCR studies demonstrated that T0901317 decreased the binding of PPAR gamma to the PPAR-responsive element (PPRE) of the adiponectin promoter in a dose-dependent manner. Furthermore, T0901317 exerted an antagonistic effect on the expression of adiponectin in adipocytes co-treated with 3 mu M Pioglitazone. In luciferase reporter gene assays, T0901317 dose-dependently inhibited PPRE-Luc activity in HEK293 cells co-transfected with LXR alpha and PPAR gamma. These results suggest that LXR activation induces insulin resistance with decreased adiponectin signaling in epididymal fat, probably due to negative regulation of PPAR gamma signaling. These findings indicate that the potential of LXR activation as a therapeutic target for atherosclerosis may be limited by the possibility of exacerbating insulin resistance-related disease.

Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells

Constitutive Activation of Peroxisome Proliferator-activated Receptor-γ Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells

PPAR Agonists Ameliorate Endothelial Cell Activation via Inhibition of Diacylglycerol–Protein Kinase C Signaling Pathway

Ppar Gamma Agonists Ameliorate Endothelial Cell Activation Via Inhibition of Diacylglycerol-Protein Kinase C Signaling Pathway - Role of Diacylglycerol Kinase

Effects of antioxidants and NO on TNF-α-induced adhesion molecule expression in human pulmonary microvascular endothelial cells

Overexpression of Adiponectin Receptors Potentiates the Antiinflammatory Action of Subeffective Dose of Globular Adiponectin in Vascular Endothelial Cells.

PPARδ Agonist Prevents Endothelial Dysfunction Via Induction of Dihydrofolate Reductase Gene and Activation of Tetrahydrobiopterin Salvage Pathway

PPARδ activation protects endothelial function in diabetic mice

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Trans‐repression of NFκB Pathway Mediated by PPARγ Improves Vascular Endothelium Insulin Resistance

Peroxisome Proliferator–Activated Receptor Δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice

Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma

Abstract 55: PPAR-δ Binding to Heme Oxygenase 1 Promoter Prevents Angiotensin II Induced Vascular and Adipocyte Dysfunction in a Model of Renovascular Hypertension

PPAR-δ in Vascular Pathophysiology

Pharmacological Activation of PPAR Gamma Ameliorates Vascular Endothelial Insulin Resistance Via a Non-Canonical PPAR Gamma-Dependent Nuclear Factor-Kappa B Trans-Repression Pathway.

PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment.

PPAR-gamma Ligands Inhibit the Expression of Inflammatory Cytokines and Attenuate Autoimmune Myocarditis.

PPAR-gamma in the Cardiovascular System.

PPAR-δin Vascular Pathophysiology

PPAR-γ in the Cardiovascular System

Inhibitory Effect of Peroxisome Proliferator Activated Receptor γ Ligands on Secretion of Inflammatory Cytokine and Matrix Metalloproteinase in Macrophages and Foam Cell